Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 2, 2011

View Archived Issues

Autologous hematopoietic stem cell therapy successfully treats children with ADA-SCID

Sanofi affiliate files MAA for tesamorelin in Brazil

Study links SNPs to secondary malignant neoplasms due to radiation for pediatric Hodgkin's lymphoma

Phosphodiesterase 5 inhibitor suppresses bladder mechanosensory activity in vivo

New 11-beta-HSD1 inhibitor has potent preclinical activity

Merck & Co. presents new gamma-secretase inhibitor as clinical candidate in Alzheimer's disease

LIST trial compares long-term effects of imidafenacin and solifenacin in OAB

Cambridge Enterprise discloses novel serotonin 5-HT1B receptor modulators

New macrocyclic coagulation factor XIa inhibitors synthesized at Bristol-Myers Squibb

Novel carbonic anhydrase inhibitors patented by European investigators

New peptidyl-prolyl cis-trans isomerase D inhibitors presented by Biotica

NattoPharma prepares new vitamin K analogues

New approval for Remicade in Canada

FDA accepts avanafil NDA

Eisai terminates development of extended-release rabeprazole sodium formulation

STADA and Gedeon Richter sign agreement for rituximab and trastuzumab biosimilars

Ardelyx closes series B financing for RDX-5791 development

AstraZeneca reports topline data from phase IIIb SATURN trial

New phase II study evaluates Dr. Reddy's DRL-17822

FDA issues drug safety communication regarding Saphris

DSMB recommends progression to higher dose in ReN-001 stem cell trial for stroke

Chugai in-licenses Japanese rights to two monoclonal antibodies

Synageva and Mitsubishi Tanabe Pharma sign research and development partnership

FDA issues update to Reclast drug label regarding risk of kidney failure

AnaptysBio completes generation of therapeutic antibodies for partner

Pevion grants CSL right of first refusal to exclusive license of candidiasis vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...